Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
2(66.7%)
Phase 1
1(33.3%)
3Total
Phase 2(2)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT00519454Unknown

Estrogen and Gender Biased Autoimmunity

Role: lead

NCT01195987Unknown

Immune Dysregulation in Hepatitis C Patients With or Without Arthritis

Role: lead

NCT00519363Phase 1Completed

Statins and Lupus: Effects of Statins on Clinical Lupus Parameters, Serological Markers and Toll-like Receptors

Role: lead

NCT00417430Phase 2Completed

Efficacy of Faslodex in Treatment of SLE Clinical, Serologic, and Molecular Studies

Role: lead

NCT00417573Phase 2Completed

Efficacy of IgIv in Patients With IgG Subclass Deficiency and Recurrent Infections

Role: lead

All 5 trials loaded